First Line and Sequential Use of Pazopanib Followed by Mammalian Target of Rapamycin (mTOR) Inhibitor Therapy among Patients with Advanced/Metastatic Renal Cell Carcinoma in a United States Community Oncology Setting

Trial description: Retrospective studies and clinical trials have investigated the sequencing of targeted therapies for the treatment of advanced renal cell carcinoma (aRCC). Specifically, the results of first-line therapy with a tyrosine-kinase inhibitor (TKI) followed by second-line therapy with different TKI and first-line TKI with a switch to a Mammalian Target of Rapamycin (mTOR) inhibitor have been evaluated. At this time, no studies have been conducted to evaluate the real-world use of pazopanib in aRCC patients treated in with first-line pazopanib then switched to an mTOR inhibitor (temsirolimus or everolimus). The objectives of this study are to assess the patient characteristics, clinical and safety outcomes, treatment patterns, and healthcare resource use (HCRU) associated with (i) aRCC patients treated with pazopanib as first-line therapy and (ii) progressive aRCC patients first treated with pazopanib followed by treatment with an mTOR inhibitor in a community oncology setting in the United States (US). This is a descriptive study; therefore no hypotheses will be tested.Data will be extracted from the McKesson Specialty Health/US Oncology Network database, which includes data from iKnowMed (iKM), Claims Data Warehouse (CDW), Social Security Death Index (SSDI), and medical record reviews.This study design will be a descriptive, retrospective, and longitudinal analysis and medical records review of eligible subjects.